HOME Press Releases Competent Cells Market worth 2.22 Billion USD by 2022



Competent Cells Market worth 2.22 Billion USD by 2022


The report "Competent Cells Market by Type (Chemically, Electrocompetent), Application (Subcloning, Phage Display Library Production, Unstable DNA Cloning, High-Throughput Cloning, Mutagenesis), End User (Pharmaceutical Companies, Academia) - Global Forecast to 2022", The competent cells market is expected to reach USD 2.22 Billion by 2022 from USD 1.37 Billion in 2017, at a CAGR of 10.2% from 2017 to 2022. The advancements in molecular cloning research due to the emergence of new technologies and the growing commercial demand for molecular cloned products and recombinant proteins are major factors that are driving the growth of this market.

     Download PDF Brochure     Speak to Analyst     Inquiry Before Buying

Browse 101 Market Data Tables and 39 Figures spread through 159 Pages and in-depth TOC on "Competent Cells Market by Type (Chemically, Electrocompetent), Application (Subcloning, Phage Display Library Production, Unstable DNA Cloning, High-Throughput Cloning, Mutagenesis), End User (Pharmaceutical Companies, Academia) - Global Forecast to 2022"
https://www.marketsandmarkets.com/Market-Reports/competent-cells-market-265815900.html
Early buyers will receive 10% customization on reports.

By type, the chemically competent cells segment is expected to dominate the market in 2017

Based on the type of competent cells, the market is segmented into chemically competent cells and electrocompetent cells. The growth of the chemically competent cells segment can be attributed to the rising intensity of research (due to technological advancement) and availability of government support, along with the growing market demand for molecular cloned products.

By application, the cloning segment is expected to dominate the market in 2017

Based on application, the competent cells market is broadly segmented into cloning, protein expression, and other applications. Cloning is expected to command the largest share of this market in 2017. Increasing research on cloning, driven by government support and funding is among the major factors driving market growth in this segment. The cloning application is further segmented into subcloning & routine cloning, phage display library construction, toxic/unstable DNA cloning, and high-throughput cloning. Similarly, other applications of competent cells include mutagenesis, single-stranded DNA production, lentiviral vector production, and large plasmid transformation.

By end user, the academic research institutes segment is expected to dominate the market in 2017

On the basis of end user, the competent cells market is segmented into academic research institutes, contract research organizations (CROs), and pharmaceutical & biotechnology companies. In 2017, the academic research institutes segment is expected to account for the largest share of the market. The growth of this end-user segment is driven by the increase in research funding for life science projects worldwide.

North America to dominate the competent cells market in 2017

By region, the global competent cells market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2017, North America is expected to account for the largest share of the market. This can be attributed to the increasing intensity of research due to technological advancement and increasing commercial needs for genomic and protein expressed products, in North American countries.

Key players operating in the competent cells market include Merck KGaA (Germany), Promega Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S), New England Biolabs (U.S.), Takara Bio (Japan), Agilent Technologies (U.S.), Lucigen (Epicenter) (Illumina) (U.S.), QIAGEN N.V. (Germany), OriGene Technologies (U.S.), Bioline (U.K.), Zymo Research (U.S.), Beijing TransGen Biotech Co., Ltd. (China), Source BioScience (U.K.), IBA GmBH (Germany), Genewiz (U.S.), BioDynamics Laboratory, Inc. (Japan), GCC Biotech (India), SMOBIO Technology (Taiwan), GeneScript Corporation (U.S.), Bio-Rad Laboratories (U.S.), Life Technologies (India) Pvt. Ltd., Cell Applications, Inc. (U.S.), Delphi Genetics (Belgium), Scarab Genomics, LLC (U.S.), and Yeastern Biotech Co., Ltd. (Taiwan).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports